ASCO Welcomes Tobacco Bill

Publication
Article
OncologyONCOLOGY Vol 15 No 6
Volume 15
Issue 6

The American Society of Clinical Oncology (ASCO) is backing legislation (H.R. 1097) that would give the Food and Drug Administration (FDA) the authority to regulate tobacco products. The legislation explicitly states that nicotine should be

The American Society of Clinical Oncology (ASCO) is backinglegislation (H.R. 1097) that would give the Food and Drug Administration (FDA) the authority to regulate tobacco products. The legislationexplicitly states that nicotine should be regulated as a drug, and tobaccoproducts as drug delivery devices. The legislation also gives the FDA theauthority to regulate tobacco product advertising and promotion. Reps. GregGanske (R-Iowa), John Dingell (D-Mich), and Henry Waxman (D-Calif) are theprimary sponsors.

"We greatly appreciate the consistent leadership Reps.Ganske, Dingell, and Waxman provide on behalf of the federal regulation oftobacco products," said an ASCO statement. "Smoking accounts for atleast 30% of all cancer deaths, is a major cause of heart disease, and isassociated with conditions ranging from colds and gastric ulcers to chronicbronchitis, emphysema, and cerebrovascular disease."

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content